Jeffrey Gelfand, MD
Neurology · San Francisco, CANPI 1205009115
Payments from drug & device makers
Across 105 payments — averaging $9658.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$1M
- F. Hoffmann-la Roche AG$2K
- Roche Products Limited$85
- MDD US Operations, LLC$83
- Mallinckrodt Hospital Products Inc.$64
- TG Therapeutics, Inc.$21
Across 19 payments — averaging $793.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$11K
- Biogen$5K
What the payments were for
- Speaking & faculty fees$2,01282%
- Food & beverage$38916%
- Education$643%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 93 | $1,011,708 |
| F. Hoffmann-la Roche AG | 8 | $2,212 |
| Roche Products Limited | 1 | $85 |
| MDD US Operations, LLC | 1 | $83 |
| Mallinckrodt Hospital Products Inc. | 1 | $64 |
| TG Therapeutics, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OCREVUS$2,012
How this compares
$1,014,172 in reported general payments places this provider in the 95th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 17 | $201,474 |
| Glatiramer Acetate | 20 | $74,059 |
| Dalfampridine ErDalfampridine | 68 | $22,080 |
| FingolimodFingolimod Hcl | 25 | $9,436 |
| Mycophenolate Mofetil | 25 | $2,133 |
| Baclofen | 42 | $1,744 |
| Teriflunomide | 23 | $1,457 |
| Carbamazepine ErCarbamazepine | 17 | $1,322 |
| Propranolol Hcl ErPropranolol Hcl | 11 | $1,138 |
| Gabapentin | 38 | $988 |
| Levetiracetam | 22 | $865 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 12 | $794 |
| Modafinil | 15 | $477 |
| Carbamazepine | 11 | $314 |
| Lamotrigine | 34 | $203 |
Paid to pharmacies, not to this prescriber.
Other neurology in San Francisco
- Bruce CreeSan Francisco$8M
- Stanley PrusinerSan Francisco$6.5M
- Adam BoxerSan Francisco$5.5M
- Jennifer ClarkeSan Francisco$5.1M
- Nancy Ann Oberheim BushSan Francisco$4.6M
- Emmanuelle WaubantSan Francisco$3M
- Jill OstremSan Francisco$2M
- William JagustSan Francisco$2M
- Gil RabinoviciSan Francisco$1.9M
- Jonathan KatzSan Francisco$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.